Standard Route for Artesunate
Artesunate, an antimalarial drug, is most commonly given intravenously (IV) for severe malaria cases, as it achieves rapid blood levels to fight Plasmodium parasites. The World Health Organization recommends IV artesunate as first-line treatment in such scenarios.[1]
Rectal Administration Option
Rectal suppositories provide an alternative when IV access is unavailable, such as in remote areas or emergencies. This route delivers the drug effectively for initial treatment before transferring to IV or oral therapy. Studies show rectal artesunate achieves therapeutic levels within hours, buying time for further care.[2][3]
Oral and Intramuscular Routes
Oral tablets exist for less severe malaria or follow-up after IV/rectal initiation, though absorption can vary with vomiting. Intramuscular (IM) injection is another option in some settings, particularly where IV isn't feasible, with comparable efficacy in clinical trials.[1][4]
When to Use Each Route
IV suits hospitalized patients with severe symptoms. Rectal works for pre-hospital or community use in high-burden areas like sub-Saharan Africa. Oral transitions patients to outpatient care, while IM bridges gaps in resource-limited clinics. Choice depends on patient condition, setting, and drug availability—no single route fits all.[1][3]
Limitations and Evidence
Rectal and IM routes have slower peak levels than IV but are lifesavers in field conditions. Pediatric formulations exist for rectal use. No subcutaneous or inhaled routes are standard. Data from randomized trials confirm non-IV options reduce mortality comparably when followed by full courses.[2][4]
Sources
[1]: WHO Guidelines for Malaria Treatment
[2]: NEJM: Rectal Artesunate for Severe Malaria
[3]: Lancet: Pharmacokinetics of Rectal Artesunate
[4]: CDC Malaria Treatment